What Is Gardasil 9? FDA Approval, Licensing in Türkiye, and Reimbursement Status
In this article
🧬 What Is Gardasil 9? (Introduction and Why It Matters)
Gardasil 9, targeting human papillomavirus (Human Papillomavirus) types, is produced using recombinant technology and contains no live virus. It is a prophylactic (preventive) vaccine. Gardasil 9 is based on virus-like particles from nine different human papillomavirus types, using their L1 capsid protein to stimulate the immune system to produce strong neutralizing antibodies against these types.
📌 Coverage
Vaccine types (nine in total):
- 6 and 11: Responsible for the vast majority of genital warts.
- 16, 18, 31, 33, 45, 52, 58: Associated particularly with cervical cancer, as well as anal, vulvar, vaginal, penile, and oropharyngeal cancers.
🏷️ Basic Definitions
- Virus-like particle: A protein shell structurally resembling a virus, without genetic material or the ability to cause infection.
- Preventive vaccine: Vaccination providing protection by establishing immunity before disease begins.
- Intramuscular administration: Usually injected into the deltoid or thigh muscle.
Gardasil 9 aims to establish immune memory before first exposure to human papillomavirus, thereby preventing viral attachment to epithelial cells, entry into cells, and initiation of persistent infection at an early stage. Gardasil 9 is not a therapeutic but a protective vaccine; screening programs (e.g., cervical smears and human papillomavirus DNA tests) should continue after vaccination.
⚙️ Mechanism of Action (Step by Step)
1) Virus-like particle structure
Gardasil 9 contains recombinant human papillomavirus L1 capsid protein -based virus-like particles . These structurally resemble actual human papillomavirus but contain no deoxyribonucleic acid (DNA) ; therefore, they do not cause infection and cannot replicate within cells.
2) Stimulation of the Natural Immune Response
After intramuscular administration, antigen-presenting cells take up virus-like particles and carry them to lymph nodes. In particular, B lymphocytesproduce, against the L1 protein, high-titer, type-specific neutralizing antibodies . Helper T lymphocytes and antigen presentation (e.g., through the major histocompatibility complex) support antibody-response maturation, establishing immune memory in the process.
3) Protective Blockade (Neutralization)
When a vaccinated person later encounters actual human papillomavirus, circulating and mucosal neutralizing antibodies bind to target L1 protein regions . Viral attachment to epithelial cells and cell entry are thus blocked early. This entry-blocking effect interrupts the chain of viral replication, persistent infection, and progression to disease.
4) Type-Specific, Broad Protection
Gardasil 9 contains virus-like particles targeting L1 proteins specific to nine human papillomavirus types. It therefore covers both high-risk carcinogenic types (e.g., sixteen, eighteen, thirty-one, thirty-three, forty-five, fifty-two, fifty-eight) and genital wart-causing types (six and eleven). Type-specific immunity provides a strong basis for protection even during possible future cross-exposures.
🔎 What Does This Mean Clinically?
- A front-door defense against infection: Neutralization before cell entry interrupts the disease chain at its beginning.
- A core cancer prevention strategy: Preventing persistent infection by high-risk types helps reduce lifetime risk of cervical and related cancers.
- Population-level protection: Widespread vaccination reduces circulating human papillomavirus burden and strengthens indirect protection.
⚠️ Important Note
Gardasil 9 is not a therapeutic vaccine. It does not eliminate existing human papillomavirus infection, lesions, or cancer. Screening and clinical follow-up should continue just as carefully after vaccination.
📜 FDA Approval Process – Timeline
The approval process for Gardasil and Gardasil 9 by the United StatesFood and Drug Administrationmarks an important turning point in human papillomavirus vaccination strategies. The timeline below summarizes the historical expansion to different age groups and indications:
- June 2006: Initial Gardasil (quadrivalent) approval for precursors of cervical, vulvar, and vaginal cancers and genital warts in females aged 9–26.
- 2009: Approved for males aged 9–26.
- 2010: Additional approval for anal cancer and anal intraepithelial neoplasia.
- December 2014: Initial Gardasil 9 (nine-valent) approval for females aged 9–26 and males aged 9–15.
- 2015–2016: Male indication expanded to ages 16–26.
- October 2018: Additional approval for adults aged 27–45 (expanded age range).
- Current: Widely used as a prophylactic vaccine in females and males aged 9–45.
🇹🇷 Licensing and Reimbursement in Türkiye
Gardasil 9 licensing and reimbursement in Türkiye also matter to national health strategies:
📅 Licensing Information
- First License Date: November 21, 2019
- License Holder: Merck Sharp Dohme İlaçları Ltd. Şti.
- License Number: 2019/600
- Distribution: Through MSD Türkiye
💰 Reimbursement and Pricing
- Gardasil 9 is not included in the National Vaccination Schedule.
- Social Security Institution (SGK) does not reimburse it.
- Some local municipal and social support projects may provide it free or at a discount.
- Current price: 4,668.24 TL (may vary with pharmacy or institutional stocks).
⚠️ Information
The lack of Gardasil 9 reimbursement in Türkiye limits access. However, because of its important role in cancer prevention, administration on a physician’s recommendation is advised, particularly for high-risk individuals.
🔬 Absorption, Distribution, Metabolism, and Elimination (ADME)
💉 Absorption
Gardasil 9 is administered byintramuscularinjection. Antigen-presenting cells take up virus-like particles (VLPs) at the injection site. This vaccine does not undergo conventional oral absorption in the usual sense.
🌐 Distribution
Virus-like particles are carried from the injection site to regional lymph nodes . Unlike small-molecule drugs, they do not circulate freely throughout the body or enter cells.
⚙️ Metabolism
Virus-like particles undergo proteolytic degradation into protein building blocks . Antigens are presented to the immune system through the major histocompatibility complex (MHC) in this process.
🚪 Elimination
Degraded proteins and peptides are eliminated through physiological pathways. Unlike small-molecule drugs, no conventional half-life value is defined.
🔗 Drug and Vaccine Interactions
- Coadministration with live vaccines: Preferably not given together; if necessary, use different injection sites and separate syringe sets.
- Immunosuppressive treatments: Corticosteroids, chemotherapy, or immunomodulators may reduce antibody responses; a 3-dose schedule is recommended.
- Combination with inactivated vaccines: Generally safe; different injection sites are recommended.
⚠️ Side-Effect Profile
🟢 Common (≥1/10)
- Injection-site pain, swelling, and redness
- Headache
- Mild fever
🟡 Intermediate Frequency (≥1/100 – <1/10)
- Nausea and dizziness
- Weakness
- Muscle and joint pain
🔴 Rare (<1/1000)
- Serious allergic reactions (anaphylaxis, angioedema)
- Syncope (fainting)
Overall Safety: Most side effects are mild and temporary; serious events are very rare. After vaccination, brief observation is recommended.
🩺 Precautions
- Pregnancy: Not routinely administered. If pregnancy is identified, subsequent doses are postponed until after delivery.
- Breastfeeding: Generally safe; monitor the mother for local reactions.
- Allergy: Contraindicated with a history of serious allergy to a previous human papillomavirus vaccine or its ingredients.
- Febrile illness: Postpone with high fever; a mild upper respiratory infection is not a barrier.
- Syncope risk: May occur particularly in adolescents; remain seated for 15 minutes after vaccination.
- Thrombocytopenia/bleeding disorder: Apply pressure after injection to control bleeding.
- Immunosuppression: Protection may decrease; dosing intervals should be replanned according to treatment.
- Concurrent vaccines: Use different sites and inform patients about local reactions.
- Patient information: Gardasil 9 is not therapeutic; screening programs should continue after vaccination.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.